Evidence map›Paper›PMID 25606972›Full record

ArticleViruses2015

Identification of a novel human rhinovirus C type by antibody capture VIDISCA-454.

Seyed Mohammad Jazaeri Farsani, Bas B Oude Munnink, Marta Canuti, Martin Deijs, Matthew Cotten, Maarten F Jebbink, Joost Verhoeven, Paul Kellam, Katherine Loens, Herman Goossens and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Seyed Mohammad Jazaeri FarsaniLaboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam 1105 AZ, the Netherlands. s.m.jazaerifarsani@amc.uva.nl.
Bas B Oude MunninkLaboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam 1105 AZ, the Netherlands. b.b.oudemunnink@amc.uva.nl.
Marta CanutiLaboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam 1105 AZ, the Netherlands. marta.canuti@gmail.com.
Martin DeijsLaboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam 1105 AZ, the Netherlands. m.deijs@amc.uva.nl.
Matthew CottenDepartment of Virus Genomics, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK. mc13@sanger.ac.uk.
Maarten F JebbinkLaboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam 1105 AZ, the Netherlands. m.f.jebbink@amc.uva.nl.
Joost VerhoevenLaboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam 1105 AZ, the Netherlands. verhoevenjtp@googlemail.com.
Paul KellamDepartment of Virus Genomics, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK. pk5@sanger.ac.uk.
Katherine LoensDepartment of Medical Microbiology, Vaccine and Infectious Disease Institute, University Hospital, Antwerp B-2650, Belgium. katherine.loens@uza.be.
Herman GoossensDepartment of Medical Microbiology, Vaccine and Infectious Disease Institute, University Hospital, Antwerp B-2650, Belgium. herman.goossens@uza.be.
Margareta IevenDepartment of Medical Microbiology, Vaccine and Infectious Disease Institute, University Hospital, Antwerp B-2650, Belgium. greet.ieven@uza.be.
Lia van der HoekLaboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam 1105 AZ, the Netherlands. c.m.vanderhoek@amc.uva.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Causative agents for more than 30 percent of respiratory infections remain unidentified, suggesting that unknown respiratory pathogens might be involved. In this study, antibody capture VIDISCA-454 (virus discovery cDNA-AFLP combined with Roche 454 high-throughput sequencing) resulted in the discovery of a novel type of rhinovirus C (RV-C). The virus has an RNA genome of at least 7054 nt and carries the characteristics of rhinovirus C species. The gene encoding viral protein 1, which is used for typing, has only 81% nucleotide sequence identity with the closest known RV-C type, and, therefore, the virus represents the first member of a novel type, named RV-C54.

Indexed as

Antibodies, ViralGenome, ViralSequence Analysis, DNAAdultCluster AnalysisFemaleHumansMolecular Sequence DataPhylogenyPicornaviridae InfectionsRespiratory SystemRespiratory Tract InfectionsRhinovirusRNA, ViralSequence HomologyAntibodies, ViralRNA, Viral

Identifiers

PMID25606972
PMCPMC4306836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.